Icatibant Universal Farma

Icatibant, the active ingredient in Icatibant Universal Farma, is a Bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with confirmed HAE.

GNH USA supplies Icatibant Universal Farma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is used to treat conditions mediated by excessive bradykinin activity, primarily hereditary angioedema.

- Hereditary angioedema type I: Provides rapid relief of acute swelling episodes in patients with C1‑inhibitor deficiency. - Hereditary angioedema type II: Reduces edema and associated pain during acute attacks in patients with dysfunctional C1‑inhibitor. - Hereditary angioedema with normal C1‑inhibitor (HAE‑nC1‑INH): Controls sudden swelling attacks in patients with genetically confirmed HAE‑nC1‑INH.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic response.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient local edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: sudden drop in blood pressure. - Angioedema unrelated to HAE: unexpected swelling in other body parts. - Urticaria: widespread hives. - Severe injection‑site necrosis: tissue damage at the site. - Life‑threatening allergic reactions: including bronchospasm or throat swelling.

Before using Icatibant, clinicians should consider several safety measures.

- Confirm diagnosis: verify hereditary angioedema type before administration. - Monitor for hypersensitivity: observe patients for signs of allergic reaction after injection. - Evaluate cardiovascular status: caution in patients with unstable blood pressure. - Review concomitant medications: avoid concurrent use of ACE inhibitors when possible. - Pregnancy and lactation: assess risk‑benefit ratio; limited data are available. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other drugs that influence bradykinin pathways or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: increase bradykinin levels, potentially reducing Icatibant efficacy. - Estrogen‑containing contraceptives: may exacerbate angioedema frequency. - Other bradykinin antagonists: concurrent use may lead to unpredictable effects.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of gastrointestinal irritation. - Diuretics: monitor blood pressure and electrolyte balance. - Beta‑blockers: observe for altered cardiovascular response. - Antihistamines: may mask early signs of allergic reactions.